0QAH Stock Chart & Stats
$147.61
-$1.77(-1.35%)
At close: 4:00 PM EDT
$147.61
-$1.77(-1.35%)
Day’s Range― - ―
52-Week Range$81.90 - $157.92
Previous CloseN/A
Volume7.13K
Average Volume (3M)31.39K
Market Cap
$365.88B
Enterprise Value$364.17B
Total Cash (Recent Filing)$7.14B
Total Debt (Recent Filing)$53.91B
Price to Earnings (P/E)119.0
Beta1.17
Next Earnings
Oct 29, 2026EPS Estimate
2.1Next Dividend Ex-DateN/A
Dividend Yield2.29%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,467,171,600
10 Day Avg. Volume16,350
30 Day Avg. Volume31,386
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.48
Enterprise Value/Gross Profit7.28
Enterprise Value/Ebitda26.15
Forecast
1Y Price Target
$159.76Price Target Upside8.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)2.65
Revenue Forecast (FY)$67.05B
Bulls Say, Bears Say
Bulls Say
Cash GenerationRobust and improving free cash flow gives Merck internally generated funds to support dividends, repurchases, debt service, and pipeline investment. Healthy cash conversion provides resilience when reported earnings fluctuate and strengthens the company’s ability to sustain strategic spending.
Commercial MomentumPositive quarterly growth and raised, narrowed guidance indicate that Merck’s core commercial platform remains capable of producing expansion despite a mature portfolio. Continued execution across multiple products can support more predictable revenue over the next several quarters.
Pipeline And DiversificationProgress across oncology, immunology, infectious disease, and other pipeline programs improves the prospect of replenishing future growth as existing products mature. Animal Health diversification further broadens revenue sources beyond human pharmaceuticals and reduces reliance on one therapeutic area.
Bears Say
Profitability DeclineThe sharp TTM profitability decline reduces earnings predictability and weakens returns on the company’s substantial capital base. If lower margins persist, Merck may have less flexibility to absorb development costs, fund acquisitions, or offset pressure from product-cycle changes.
Keytruda SC Patent RiskThe European injunction directly constrains commercialization of Keytruda’s subcutaneous formulation across several markets, limiting a route for administration-based lifecycle expansion. Although intravenous Keytruda remains available, the ruling creates ongoing regulatory and legal uncertainty around the SC opportunity.
Pipeline SetbackWithdrawal of the application delays potential access to a new oncology indication and demonstrates that not all late-stage assets will translate into near-term commercialization. Continued Phase 3 enrollment preserves optionality, but approval timing and development costs remain uncertain.
Merck & Company News
0QAH FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest share price was $81.90 and its highest was $157.92 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $365.88B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 29, 2026 which is in 5 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Aug 04, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.14.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 2.29%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.1.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,467,171,600 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 1.187%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in GB:0QAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$159.76 (8.23% Upside)
$159.76 (8.23% Upside)
Blogger Sentiment
Bullish
GB:0QAH Sentiment 74%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 81%
Bearish news 19%
Bearish news 19%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.99%
12-Months-Change
Fundamentals
Return on Equity
6.60%
Trailing 12-Months
Asset Growth
10.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
0QAH Company Deck
0QAH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and scientific story: core revenue growth (Q2 +5%), several strong product performances (KEYTRUDA, WELIREG, WINREVAIR), meaningful vaccine and pneumococcal momentum, multiple important regulatory approvals and positive Phase III readouts (LIPFENDRA approval, sac-TMT, tulisokibart induction, islatravir combos), and raised/narrowed revenue guidance. Offsetting these positives are material one-time charges from the Terns acquisition that produced a GAAP loss and drove a volatile tax rate, margin and expense pressure, one clinical setback (SSc-ILD), and some near-term commercial headwinds (OHTUVAYRE unwind, moderating KEYTRUDA U.S. growth). Overall, management emphasized pipeline derisking, continued launches, and long-term opportunity, while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.View all GB:0QAH earnings summaries0QAH Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
0QAH Stock 12 Month Forecast
Average Price Target
$159.76
▲(8.23% Upside)